A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on high-certainty data, offering new options for those with mild to severe disease.

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Shares of Nektar Therapeutics soared after the company said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin. The stock was up 31% at $12.49 in Monday's ...

USA: Researchers have discovered in a new study that young children with moderate-to-severe atopic dermatitis (AD) tend to be ...

Early childhood atopic dermatitis does not affect executive function during middle childhood, particularly in those with mild phenotypes.